Premium
Genomic study suggests value of genotype‐based dosing
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30692
Subject(s) - dosing , cyp2d6 , genotyping , medicine , cyp2c19 , pharmacogenetics , antidepressant , antipsychotic drug , pharmacology , pharmacogenomics , genotype , antipsychotic , drug , genetics , biology , schizophrenia (object oriented programming) , psychiatry , gene , hippocampus
A systematic review and meta‐analysis has identified differences in antidepressant and antipsychotic drug exposure between patients with various levels of genetically associated drug metabolism capacity. These results suggest the basis for using CYP2C19 and CYP2D6 genotyping data to guide dosing recommendations for antidepressants and antipsychotics.